| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2853749 | The American Journal of Cardiology | 2015 | 4 Pages |
Abstract
In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of the ST2 pathway in clinical disease, including evidence that sST2 could be a useful biomarker in both allergic and nonallergic pulmonary disease.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ednan K. Bajwa, Alexandre Mebazaa, James L. Januzzi,